Search clinical trials for: marginal zone lymphomas

Total 2588 results

National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | CLL (Chronic Lymphocytic Leukemia) | Monoclonal B-Cell Lymphocytosis

United States
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Follicular Lymphoma | Marginal Zone Lymphoma | DLBCL | CLL | MCL | Indolent Lymphoma | Richter's Transformation | SLL | Mediastinal Large B-cell Lymphoma | Aggressive Lymphoma

United States
AstraZeneca
Parexel

Active, not recruiting

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

United States, Korea, Republic of, Canada, United Kingdom, Spain, France, Denmark
Jonathan Friedberg
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma (ILyAD)

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Mucosal-Associated Lymphoid Tissue Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Completed

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Non-Small-Cell Lung Carcinoma

Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell Carcinoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Indolent Non-hodgkin Lymphoma

China
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditions

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Lymphoma, Non-Hodgkin | B-cell Lymphoma | Multiple Myeloma | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, B-cell Marginal Zone

United States, France, Poland, Italy
University of Washington
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Transformed... and other conditions

United States
Massachusetts General Hospital
TG Therapeutics

Terminated

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2

United States
Celgene

Active, not recruiting

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (MAGNIFY)

Lymphoma, Non-Hodgkin

United States, Germany, Puerto Rico
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

Marginal Zone Lymphoma of Ocular Adnexal

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma

Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditions

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States, Canada, Italy
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma | Chronic Lymphocytic Lymphoma

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

MZL

China
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Lymphoplasmacytic... and other conditions

United States, Canada
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
Beth Christian
Genentech, Inc.; Celgene

Active, not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Burkitt Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Precancerous/Nonmalignant Condition
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid... and other conditions

United States
Central South University

Completed

A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine

Major Depressive Disorder

China
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.

Active, not recruiting

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

B-cell Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Korea, Republic of, Australia, Japan, United Kingdom, Italy, Poland, France, Switzerland, Sweden
University of Colorado, Denver

Completed

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma

United States
ArQule, Inc., a subsidiary of Merck Sharp & Dohme...

Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Lymphoma, B-Cell | Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Richter's Transformation

United States
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Kite, A Gilead Company

Active, not recruiting

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-Hodgkin Lymphoma

United States, France
Boryung Pharmaceutical Co., Ltd

Active, not recruiting

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Follicular Lymphoma | B Cell Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Small Lymphocytic Leukemia

Korea, Republic of, United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Lymphoma | Leukemia | Graft Versus Host Disease

United States
Kami Maddocks, MD
Pharmacyclics LLC.

Active, not recruiting

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
BeiGene

Active, not recruiting

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Mature B-cell Malignancies

Japan
University Hospital Southampton NHS Foundation...

Completed

Immune Responses to COVID-19 Vaccination in Lymphoma Patients (PROSECO)

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Classical Hodgkin Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Nodular Lymphocyte... and other conditions

United Kingdom
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Lymphoma

Belgium, United States, France, Israel, Italy, United Kingdom, Germany, Spain, Poland, Australia, Argentina, Denmark
Ottawa Heart Institute Research Corporation

Active, not recruiting

The COVID-RASi Trial (COVID-19)

Cardiovascular Diseases | COVID-19

Brazil, Canada, Mexico
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Lymphoma

United States
MEI Pharma, Inc.

Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland

Search clinical trials for: marginal zone lymphomas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations